The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease
- PMID: 22021174
- PMCID: PMC4020145
- DOI: 10.1002/mds.23884
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease
Abstract
The Movement Disorder Society (MDS) Task Force on Evidence-Based Medicine (EBM) Review of Treatments for Parkinson's Disease (PD) was first published in 2002 and was updated in 2005 to cover clinical trial data up to January 2004 with the focus on motor symptoms of PD. In this revised version the MDS task force decided it was necessary to extend the review to non-motor symptoms. The objective of this work was to update previous EBM reviews on treatments for PD with a focus on non-motor symptoms. Level-I (randomized controlled trial, RCT) reports of pharmacological and nonpharmacological interventions for the non-motor symptoms of PD, published as full articles in English between January 2002 and December 2010 were reviewed. Criteria for inclusion and ranking followed the original program outline and adhered to EBM methodology. For efficacy conclusions, treatments were designated: efficacious, likely efficacious, unlikely efficacious, non-efficacious, or insufficient evidence. Safety data were catalogued and reviewed. Based on the combined efficacy and safety assessment, Implications for clinical practice were determined using the following designations: clinically useful, possibly useful, investigational, unlikely useful, and not useful. Fifty-four new studies qualified for efficacy review while several other studies covered safety issues. Updated and new efficacy conclusions were made for all indications. The treatments that are efficacious for the management of the different non-motor symptoms are as follows: pramipexole for the treatment of depressive symptoms, clozapine for the treatment of psychosis, rivastigmine for the treatment of dementia, and botulinum toxin A (BTX-A) and BTX-B as well as glycopyrrolate for the treatment of sialorrhea. The practical implications for these treatments, except for glycopyrrolate, are that they are clinically useful. Since there is insufficient evidence of glycopyrrolate for the treatment of sialorrhea exceeding 1 week, the practice implication is that it is possibly useful. The treatments that are likely efficacious for the management of the different non-motor symptoms are as follows: the tricyclic antidepressants nortriptyline and desipramine for the treatment of depression or depressive symptoms and macrogol for the treatment of constipation. The practice implications for these treatments are possibly useful. For most of the other interventions there is insufficient evidence to make adequate conclusions on their efficacy. This includes the tricyclic antidepressant amitriptyline, all selective serotonin reuptake inhibitors (SSRIs) reviewed (paroxetine, citalopram, sertraline, and fluoxetine), the newer antidepressants atomoxetine and nefazodone, pergolide, Ω-3 fatty acids as well as repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression or depressive symptoms; methylphenidate and modafinil for the treatment of fatigue; amantadine for the treatment of pathological gambling; donepezil, galantamine, and memantine for the treatment of dementia; quetiapine for the treatment of psychosis; fludrocortisone and domperidone for the treatment of orthostatic hypotension; sildenafil for the treatment of erectile dysfunction, ipratropium bromide spray for the treatment of sialorrhea; levodopa/carbidopa controlled release (CR), pergolide, eszopiclone, melatonin 3 to 5 mg and melatonin 50 mg for the treatment of insomnia and modafinil for the treatment of excessive daytime sleepiness. Due to safety issues the practice implication is that pergolide and nefazodone are not useful for the above-mentioned indications. Due to safety issues, olanzapine remains not useful for the treatment of psychosis. As none of the studies exceeded a duration of 6 months, the recommendations given are for the short-term management of the different non-motor symptoms. There were no RCTs that met inclusion criteria for the treatment of anxiety disorders, apathy, medication-related impulse control disorders and related behaviors other than pathological gambling, rapid eye movement (REM) sleep behavior disorder (RBD), sweating, or urinary dysfunction. Therefore, there is insufficient evidence for the treatment of these indications. This EBM review of interventions for the non-motor symptoms of PD updates the field, but, because several RCTs are ongoing, a continual updating process is needed. Several interventions and indications still lack good quality evidence, and these gaps offer an opportunity for ongoing research. © 2011 Movement Disorder Society.
Copyright © 2011 Movement Disorder Society.
Conflict of interest statement
Similar articles
-
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.Mov Disord. 2011 Oct;26 Suppl 3:S2-41. doi: 10.1002/mds.23829. Mov Disord. 2011. PMID: 22021173 Review.
-
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.Mov Disord. 2005 May;20(5):523-39. doi: 10.1002/mds.20464. Mov Disord. 2005. PMID: 15818599 Review.
-
Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Mov Disord. 2019. PMID: 30653247 Free PMC article. Review.
-
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.Mov Disord. 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23. Mov Disord. 2018. PMID: 29570866 Review.
-
Emerging drugs for autonomic dysfunction in Parkinson's disease.Expert Opin Emerg Drugs. 2013 Mar;18(1):39-53. doi: 10.1517/14728214.2013.766168. Epub 2013 Feb 1. Expert Opin Emerg Drugs. 2013. PMID: 23373820 Review.
Cited by
-
Management of motor and non-motor symptoms in Parkinson's disease.CNS Drugs. 2013 Apr;27(4):259-72. doi: 10.1007/s40263-013-0053-2. CNS Drugs. 2013. PMID: 23515972 Review.
-
Management of neuropsychiatric symptoms in long-term care residents with Parkinson's disease: a retrospective cohort study.Drugs Aging. 2013 Jan;30(1):19-22. doi: 10.1007/s40266-012-0038-8. Drugs Aging. 2013. PMID: 23188751
-
A machine learning and network framework to discover new indications for small molecules.PLoS Comput Biol. 2020 Aug 7;16(8):e1008098. doi: 10.1371/journal.pcbi.1008098. eCollection 2020 Aug. PLoS Comput Biol. 2020. PMID: 32764756 Free PMC article.
-
Neuroprotective effects of Ginkgo biloba dropping pills in Parkinson's disease.J Pharm Anal. 2021 Apr;11(2):220-231. doi: 10.1016/j.jpha.2020.06.002. Epub 2020 Jun 20. J Pharm Anal. 2021. PMID: 34012698 Free PMC article.
-
Cognitive Function in Parkinson's Disease Patients with and without Anxiety.Neurol Res Int. 2016;2016:6254092. doi: 10.1155/2016/6254092. Epub 2016 Oct 9. Neurol Res Int. 2016. PMID: 27800180 Free PMC article.
References
-
- Lim SY, Lang AE. The nonmotor symptoms of Parkinson's disease—an overview. Mov Disord. 2010;25(Suppl 1):S123–S130. - PubMed
-
- Poewe W. The natural history of Parkinson's disease. J Neurol. 2006;253(Suppl 7):VII2–VII6. - PubMed
-
- Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-l-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20:190–199. - PubMed
-
- Sackett DL, Straus S, Richardson S, Rosenberg W, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. 2nd. London: Churchill Livingstone; 2000.
-
- Goetz C, Koller W, Poewe W. Management of Parkinson's disease: an evidence-based review. Mov Disord. 2002;17(Suppl 4):1–166. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous